In brief
- On September 3, the FDA opened a public docket (FDA-2026-N-9550) to review the development of botanical-based medicines.
- The agency’s definition of this category includes plant material, algae, and macroscopic fungi.
- Only four botanical products have reached the US market as prescription drugs. The deadline for submitting comments is November 3.
The US Food and Drug Administration wants to know what is hindering the development of drugs made from plant or fungal matter. The announcement was made public on September 3, and the formal request appeared the following day in the Federal Register under docket number FDA-2026-N-9550. Anyone can submit a response until November 3.
A request for information, not a regulation
It is important not to confuse the nature of this action. What the FDA has opened is a request for information: a channel to collect data and opinions before making any decisions. It does not change any rules today, approve anything, or reclassify any substances. The text asks about obstacles faced by researchers, approaches to accelerate development, potential updates to guidelines, quality standards, trial designs suitable for complex mixtures rather than single molecules, and the role of evidence gathered outside of clinical trials.
The announcement is signed by Kyle Diamantas, acting commissioner, and Marta Sokolowska, deputy director of the FDA center responsible for substance use and behavioral health.
Four drugs in history
The statistic that explains this consultation is brief: four. That is the number of botanical products approved in the United States as prescription drugs via the new drug and biological license pathways. Three contain sinecatechins, crofelemer, and birch triterpenes; the fourth is anacaulasa. Compared to the thousands of synthetic drugs authorized, the figure speaks for itself.
The technical reason is well known. A plant or fungal extract is not a single substance, but a collection of compounds whose proportions vary according to the species, soil, harvest, and extraction method. Regulatory machinery is built on the premise of an identical and reproducible dose, and a living mixture fits poorly into that mold. The FDA defines these products as those derived from plant material, algae, or macroscopic fungi, or combinations of the three.
What this has to do with psychedelics
Neither the press release nor the Federal Register notice mentions psychedelics. Nor does it mention cannabis. The connection lies in the definition: macroscopic fungi and plant material are, precisely, the raw materials from which psilocybin, peyote and San Pedro mescaline, ibogaine from the iboga root, or ayahuasca brews are derived.
Almost all clinical development currently underway works with isolated molecules synthesized in a laboratory. Anyone wishing to investigate a full preparation, with its mixture of alkaloids, faces a much less traveled path. The FDA explicitly asks about this in the docket: what difficulties are posed by developing whole-plant or minimally purified products compared to highly purified isolates? If this leads to clearer criteria for complex mixtures, that path could become somewhat more viable.
What it implies
For now, it is little more than a door left ajar. A request for information can lead to a revised guideline or to nothing at all; the history of these types of dockets is inconsistent, and timelines are measured in years. The agency has already scheduled a joint workshop with the European Medicines Agency on September 25 regarding herbal medicinal products. It also does not change the legal status of any plant or fungus: we are talking about drug development, not personal use. What it does offer is a path for participation with a deadline, open until November 3 at regulations.gov.
Source
- FDA. FDA Seeks Public Input to Advance Development of Botanical Drug Products. Food and Drug Administration press release, September 3, 2026.
- Advancing Development of Botanical Drug Products; Request for Information. Federal Register, September 4, 2026 (docket FDA-2026-N-9550).
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
